Table 2 Stage of diagnosis before and during the COVID-19 Pandemic (n = 167)
Variable | Pre-COVID- 19 Era (2016–2019) | P-value | COVID-19 Era (2020–2022) | P-value | ||
|---|---|---|---|---|---|---|
Stage I, II n (%) 20 (22.7) | Stage III, IV n (%) 68 (77.3) | Stage I, II n (%) 12 (15.2) | Stage III, IV n (%) 67 (84.8) | |||
Age | ||||||
00–04 | 5 (25.0) | 20 (29.4) |  | 2 (16.7) | 39 (58.2) |  |
05–09 | 6 (30.0) | 13 (19.1) | 0.764 | 3 (25.0) | 12 (17.9) | 0.029 |
10–14 | 3 (15.0) | 10 (14.7) |  | 4 (33.3) | 6 (9.0) |  |
15–19 | 6 (30.0) | 25 (36.8) |  | 3 (25.0) | 10 (14.9) |  |
Sex | ||||||
Male | 12 (60.0) | 31 (45.6) | 0.257 | 7 (58.3) | 39 (58.2) | 0.994 |
Female | 8 (40.0) | 37 (54.4) | Â | 5 (41.7) | 28 (41.8) | Â |
Region | ||||||
Kilimanjaro | 8 (40.0) | 33 (48.5) | 0.501 | 6 (50.0) | 21 (31.3) | 0.210 |
Other | 12 (60.0) | 35 (51.5) | Â | 6 (50.0) | 46 (68.7) | Â |
Time travel | ||||||
Less than 1Â h | 5 (25.0) | 21 (30.9) | Â | 5 (41.7) | 11 (16.4) | Â |
Between 2–5 h | 13 (65.0) | 39 (57.4) | 0.828 | 5 (41.7) | 47 (70.1) | 0.104 |
More than 6Â h | 2 (10.0) | 8 (11.8) | Â | 2 (16.7) | 9 (13.4) | Â |
Treatment | ||||||
Radiotherapy | ||||||
No | 17 (85.0) | 64 (94.1) | 0.185 | 12 (100.0) | 57 (85.1) | 0.152 |
Yes | 3 (15.0) | 4 (5.9) | Â | 0 (0.0) | 10 (14.9) | Â |
Chemotherapy | ||||||
No | 2 (10.0) | 7 (10.3) | 0.970 | 1 (8.3) | 12 (17.9) | 0.410 |
Yes | 18 (90.0) | 61 (89.7) | Â | 11 (97.1) | 55 (82.1) | Â |
Surgery | ||||||
No | 17 (85.0) | 53 (77.9) | 0.491 | 7 (58.3) | 35 (52.2) | 0.697 |
Yes | 3 (15.0) | 15 (22.1) | Â | 5 (41.7) | 32 (47.8) | Â |
Date of last contact | ||||||
Alive | 17 (85.0) | 47 (69.1) | Â | 11 (91.7) | 52 (77.6) | Â |
Dead | 3 (15.0) | 19 (27.9) | 0.340 | 1 (8.3) | 15 (22.4) | 0.265 |
Unknown | 0 | 2 | Â | 0 | 0 | Â |